Best penny stocks 2024

best penny stocks 2024

Investing in penny stocks can be an exciting venture for investors looking to explore high-risk, high-reward opportunities in the stock market. These stocks, typically priced below $5 per share, have the potential for significant growth but also come with increased volatility. As we enter 2024, let’s explore some of the best penny stocks worth watching for potential growth opportunities.

Table of Contents

What is penny stock

A penny stock refers to a common stock that typically trades at a relatively low price, usually below $5 per share, although the exact definition may vary depending on the market or regulatory authority. These stocks are often issued by small-cap or micro-cap companies that have a low market capitalization and may trade on over-the-counter (OTC) exchanges rather than major stock exchanges like the New York Stock Exchange (NYSE) or NASDAQ. Penny stocks are known for their high volatility and speculative nature, and they may lack liquidity, making them riskier investments compared to larger, more established companies. Investors interested in penny stocks should conduct thorough research and exercise caution due to the increased potential for price fluctuations and the greater likelihood of encountering fraudulent or misleading information. Bellow our Guide for  Best Penny Stocks 2024

BioNano Genomics (BNGO)

BioNano Genomics (BNGO) is a biotechnology company specializing in genomic analysis tools. Here are some key points about BioNano Genomics:

  1. Focus on Genomic Analysis: BioNano Genomics develops and markets innovative tools and technologies for studying genomics, with a particular emphasis on structural variation analysis.

  2. Saphyr System: The company’s flagship product is the Saphyr system, which offers high-throughput genome mapping and analysis capabilities. This system enables researchers and clinicians to detect structural variations in DNA with high accuracy and resolution.

  3. Applications: BioNano Genomics’ technologies find applications in various areas, including cancer research, genetic disease diagnostics, and agricultural genomics. The company’s tools are used by researchers, clinicians, and biotech companies worldwide.

  4. Potential for Growth: With the increasing importance of genomic analysis in various fields, BioNano Genomics has the potential for significant growth. Its innovative technologies address critical needs in genomics research and clinical diagnostics, positioning the company for expansion in the coming years.

Furthermore, BioNano Genomics (BNGO) presents an appealing financial forecast. The company anticipates a 27% to 30% uptick in revenues for the fourth quarter of 2023 compared to the previous quarter. Additionally, it foresees a full-year revenue growth of 29% to 30% compared to the preceding year. Analysts on Wall Street are also optimistic about BNGO’s stock, forecasting a 31.11% surge in its top-line revenue and a significant rise in its earnings per share (EPS) during the same period.


Zomedica (ZOM)

Zomedica (ZOM) is a dynamic player in the animal health industry, focusing on developing innovative solutions for veterinary diagnostics and treatment. The company’s flagship product, TRUFORMA, is a point-of-care diagnostic platform designed to revolutionize the way veterinarians diagnose and treat their patients. With a commitment to advancing animal healthcare through cutting-edge technology, Zomedica is poised for significant growth in the coming years. As the demand for advanced veterinary diagnostics continues to rise, ZOM stands out as a promising investment opportunity for those looking to capitalize on the burgeoning animal health market.

The company projected fourth-quarter revenue to surpass $7 million, reaching a new milestone, with total annual revenue expected to exceed $25 million. This would signify a substantial increase of more than 32% compared to the previous year. ZOM’s growth can largely be attributed to a combination of its diagnostic sales and therapeutic devices, particularly its PulseVet and Assisi products.

Moving forward, the company anticipates full-year revenue to range between $31 and $35 million. This forecast indicates a potential 40% growth at the upper end of the spectrum compared to the revenue generated in 2023.

Ideanomics (IDEX)

Ideanomics (IDEX) has reported strong financial performance, with Q4 2023 revenue expected to surge between 27% and 30% compared to the previous quarter. Additionally, the company anticipates a robust full-year revenue increase of 29% to 30% from the prior year. Analysts on Wall Street share this optimism, predicting a notable 31.11% rise in the company’s top line and a substantial increase in its earnings per share (EPS) for the same period.

The company faced difficulties in the previous quarter, experiencing a significant 91.91% year-over-year decline in revenues to $670,000. Additionally, its net cash flow over the last twelve months has been negative, amounting to $64.85 million. Despite these challenges, its valuation appears compellingly low, indicated by a price-to-sales ratio of only 0.09.

Sundial Growers (SNDL)

Sundial Growers (SNDL) is a cannabis company that has garnered attention in the market due to its volatile performance. While it has shown promise in certain aspects, such as its production capacity and expansion efforts, it has also faced challenges, including fluctuations in revenue and profitability. Investors should carefully consider both the potential opportunities and risks associated with investing in SNDL

Sundial Growers’ strategic initiatives and acquisitions in recent years have set the stage for an anticipated annual revenue of $1 billion by the close of 2023, aiming for profitability by 2024. In the last quarter, SNDL disclosed revenues of $237.6 million, alongside a free cash flow of $25.62 million.

Certain analysts on Wall Street also share the sentiment that SNDL is progressing positively toward profitability, with projections indicating a positive EPS by fiscal year 2025 at the latest, coupled with anticipated revenue growth for the company.

Castor Maritime

Castor Maritime has been actively expanding its fleet, which has contributed to its growing revenue stream. In the third quarter of 2023, the company reported a significant increase in revenue compared to the previous year. Additionally, its fleet expansion strategy has positioned it for further growth in the future.

Despite facing challenges in the shipping industry, Castor Maritime has managed to maintain a positive outlook. With its focus on fleet expansion and strategic acquisitions, the company is poised to capitalize on opportunities in the maritime sector and drive future revenue growth.

I’m impressed with CTRM stock due to its strong financial position, particularly its reinforced balance sheet. It’s rare to come across a penny stock in the shipping sector that isn’t burdened by debt. In January 2024, the company announced the sale of two Panamax bulk carrier vessels, the M/V Magic Nova and the M/V Magic Horizon, for a total of $31.9 million.

Furthermore, CTRM boasts $793 million in unrestricted cash and has no outstanding debt. This financial strength positions it well for navigating through potential economic and geopolitical challenges in 2024, unlike some of its competitors.

Additionally, the company’s valuation is appealing, trading at just 0.80 times earnings and 0.32 times sales.

Phunware (PHUN)

Phunware (PHUN) is a promising investment option with a unique focus on mobile solutions for multiscreen as a service (MaaS). The company provides a comprehensive platform for brands to engage with their users through mobile applications, enabling targeted advertising, content management, and audience engagement.

In recent quarters, PHUN has demonstrated significant growth potential, with revenues increasing by 138% year-over-year in Q3 2023. Moreover, the company has successfully expanded its customer base and diversified its revenue streams through strategic partnerships and acquisitions.

Despite facing some volatility in the stock market, PHUN remains well-positioned for future growth, with a strong balance sheet and a solid pipeline of innovative products and services. As the mobile technology sector continues to evolve, PHUN could emerge as a key player in the industry, making it an attractive investment opportunity for long-term investors.

PHUN stands out as one of the top penny stocks to consider, given its impressive performance in recent quarters. During Q3 2023, PHUN disclosed net revenues of $2.8 million, primarily driven by platform and hardware sales. Analysts have also given PHUN a favorable rating of “Strong Buy,” highlighting its potential for growth and profitability


In conclusion, the world of penny stocks offers both opportunities and risks for investors. While these stocks can potentially provide significant returns, it’s important to conduct thorough research and exercise caution before investing.

If you like check our guide for best investment in 2024.

  The companies highlighted in our guide for best penny stocks 2024, including BioNano Genomics, Zomedica, Ideanomics, Sundial Growers, Castor Maritime, and Phunware, each present unique prospects and challenges. Investors should carefully evaluate their financial goals, risk tolerance, and market conditions before making any investment decisions. As always, seeking guidance from financial professionals and staying informed about market trends can help investors navigate the dynamic landscape of penny stocks.


More Posts

10 ways to lock yields above 5%


In the ever-evolving landscape of investing, securing a reliable yield above 5% is a target many investors aim for. With the current financial climate indicating

Send Us A Message is an independent, advertising-supported publisher and comparison service. We are compensated in exchange for placement of sponsored products and services, or by you clicking on certain links posted on our site. Therefore, this compensation may impact how, where and in what order products appear within listing categories, except where prohibited by law for our mortgage, home equity and other home lending products. Other factors, such as our own proprietary website rules and whether a product is offered in your area or at your self-selected credit score range, can also impact how and where products appear on this site. While we strive to provide a wide range of offers, Capitacritique does not include information about every financial or credit product or service.

Scroll to Top